Get 20M+ Full-Text Papers For Less Than $1.50/day. Start a 14-Day Trial for You or Your Team.

Learn More →

Abdominal SepsisInflammatory Mediators in Intra-abdominal Sepsis

Abdominal Sepsis: Inflammatory Mediators in Intra-abdominal Sepsis [Although the case fatality rate of sepsis is improving, the absolute mortality is growing due to increasing worldwide incidence (Suarez De La Rica et al., Ann Transl Med 4:325, 2016). Further, the annual cost of treating sepsis in the United States is estimated to be $17 billion (Sepsis Fact Sheet, http://www.nigms.nih.gov/Education/Pages/factsheet_sepsis.aspx, 2014). Abdominal sepsis is a particularly challenging type, as interventions within the abdomen are frequently required for source control, yet the most severe manifestations are systemic. While supportive intensive care therapies and surgical correction of the inciting causes improve every year, this does not directly address the storms of biomediators that cause widespread inflammation and injury ultimately causing frequent death. To date, hundreds of pharmaceutical and biological agents have been tested without finding effective pharmacologic therapy targeting the action of biomediators. Therefore, a new paradigm is necessary, such as finding a way to block access of inflammatory cytokines to the bloodstream, before they can cause systemic inflammation.] http://www.deepdyve.com/assets/images/DeepDyve-Logo-lg.png

Abdominal SepsisInflammatory Mediators in Intra-abdominal Sepsis

Part of the Hot Topics in Acute Care Surgery and Trauma Book Series
Editors: Sartelli, Massimo; Bassetti, Matteo; Martin-Loeches, Ignacio
Kirkpatrick, Andrew W.; Xiao, Jimmy; Jenne, Craig N.; Roberts, Derek J.
Abdominal Sepsis — Jun 23, 2017
Download PDF
13 pages

Loading next page...
 
/lp/springer-journals/abdominal-sepsis-inflammatory-mediators-in-intra-abdominal-sepsis-fU9wjXcwoe
Publisher
Springer International Publishing
Copyright
© Springer International Publishing AG, part of Springer Nature 2018
ISBN
978-3-319-59703-4
Pages
15 –28
DOI
10.1007/978-3-319-59704-1_2
Publisher site
See Chapter on Publisher Site

Abstract

[Although the case fatality rate of sepsis is improving, the absolute mortality is growing due to increasing worldwide incidence (Suarez De La Rica et al., Ann Transl Med 4:325, 2016). Further, the annual cost of treating sepsis in the United States is estimated to be $17 billion (Sepsis Fact Sheet, http://www.nigms.nih.gov/Education/Pages/factsheet_sepsis.aspx, 2014). Abdominal sepsis is a particularly challenging type, as interventions within the abdomen are frequently required for source control, yet the most severe manifestations are systemic. While supportive intensive care therapies and surgical correction of the inciting causes improve every year, this does not directly address the storms of biomediators that cause widespread inflammation and injury ultimately causing frequent death. To date, hundreds of pharmaceutical and biological agents have been tested without finding effective pharmacologic therapy targeting the action of biomediators. Therefore, a new paradigm is necessary, such as finding a way to block access of inflammatory cytokines to the bloodstream, before they can cause systemic inflammation.]

Published: Jun 23, 2017

There are no references for this article.